Free tool
FAERS Monitor: Zimhi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212854 or its brand name (Zimhi, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
933
Serious
752
81% of reports
Hospitalization
409
Death reported
140
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective97
- toxicity to various agents90
- vomiting58
- fatigue49
- off label use49
- overdose48
- drug withdrawal syndrome46
- nausea46
- diarrhoea40
- pain40
- febrile neutropenia32
- fall31
- unresponsive to stimuli31
- drug abuse30
- drug dependence30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 10 |
| 2010 | 8 |
| 2011 | 3 |
| 2012 | 9 |
| 2013 | 9 |
| 2014 | 10 |
| 2015 | 15 |
| 2016 | 26 |
| 2017 | 35 |
| 2018 | 59 |
| 2019 | 50 |
| 2020 | 128 |
| 2021 | 85 |
| 2022 | 106 |
| 2023 | 94 |
| 2024 | 117 |
| 2025 | 103 |
| 2026 | 59 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,226 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| unresponsive to stimuliSignal | 31 | 27.1 | 19.2 | 754 |
| toxicity to various agentsSignal | 90 | 12.0 | 9.9 | 907 |
| drug withdrawal syndromeSignal | 46 | 11.8 | 8.9 | 447 |
| febrile neutropeniaSignal | 32 | 10.9 | 7.7 | 278 |
| drug abuseSignal | 30 | 8.1 | 5.7 | 181 |
| overdoseSignal | 48 | 5.0 | 3.8 | 152 |
| drug dependenceSignal | 30 | 4.2 | 3.0 | 71 |
| vomitingSignal | 58 | 2.8 | 2.2 | 66 |
| fallSignal | 31 | 2.1 | 1.5 | 17 |
| drug ineffective | 97 | 1.7 | 1.4 | 26 |
| pain | 40 | 1.5 | 1.1 | 6 |
| fatigue | 49 | 1.4 | 1.1 | 6 |
| diarrhoea | 40 | 1.4 | 1.0 | 4 |
| nausea | 46 | 1.3 | 1.0 | 3 |
| off label use | 49 | 1.3 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.